Role of DNA hypomethylation in the development of the resistance to doxorubicin in human MCF-7 breast adenocarcinoma cells

Cancer Letters

Volumn 231, Issue 1, 2006, Pages 87-93

  Chekhun, Vasil F ^a   Kulik, Galina I ^a   Yurchenko, Olga V ^a   Tryndyak, Volodymyr P ^a   Todor, Igor N ^a   Luniv, Liliana S ^a   Tregubova, Nadiya A ^a   Pryzimirska, Tamara V ^a   Montgomery, Beverly ^b   Rusetskaya, Nataliya V ^a   Pogribny, Igor P ^b  

^a R E KAVETSKY INSTITUTE OF EXPERIMENTAL PATHOLOGY   (Ukraine)

^b NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

Author keywords

DNA hypomethylation; Doxorubicin resistance; MCF 7 cells

Indexed keywords

DNA METHYLTRANSFERASE; DOXORUBICIN; GLUTATHIONE TRANSFERASE; GLYCOPROTEIN P; GUANINE DERIVATIVE; METHYLGUANINE; UNCLASSIFIED DRUG; UROKINASE;

ARTICLE; BREAST ADENOCARCINOMA; CELL LINE; CELL STRAIN MCF 7; CONTROLLED STUDY; DNA METHYLATION; GENETIC VARIABILITY; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROMOTER REGION;

ADENOCARCINOMA; ANTIBIOTICS, ANTINEOPLASTIC; BREAST NEOPLASMS; DNA METHYLATION; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, MDR; GLUTATHIONE TRANSFERASE; HUMANS; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE; PROMOTER REGIONS (GENETICS); URINARY PLASMINOGEN ACTIVATOR;

MINK CELL FOCUS-FORMING VIRUS;

EID: 28844468518     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2005.01.038     Document Type: Article

References (21)

1. H.L. Howe, P.A. Wingo, M.J. Thun, L.A.G. Ries, H.M. Rosenberg, E.G. Feigal, and B.K. Edwards Annual report to the nation on the status of cancer (1973 through 1998), featuring cancers with recent increasing trends J. Natl Cancer Inst. 93 2001 824 842
2. A.A. Stavrovskaya Cellular mechanism of multidrug resistance of tumor cells Biochemistry 65 2000 95 106
3. M.M. Gottesman Mechanisms of cancer drug resistance Annu. Rev. Med. 53 2002 615 627
4. G.D. Kruh Introduction to resistance to anticancer agents Oncogene 22 2003 7262 7264
5. S.V. Ambudkar, C. Kimchi-Sarfaty, Z.E. Sauna, and M.M. Gottesman P-glycoprotein: from genomics to mechanism Oncogene 22 2003 7468 7485
6. K. Ueda, I. Pastan, and M.M. Gottesman Isolation and sequence of the promoter of the human multidrug-resistance (p-glycoprotein) gene J. Biol. Chem. 262 1987 17432 17436
7. T. Harada, J. Nagayama, K. Kohno, L.A. Mickley, T. Fojo, M. Kuwano, and M. Wada Alu-associated interstitial deletions and chromosomal re-arrangement in 2 human multidrug-resistant cell lines Int. J. Cancer 86 2000 506 511
8. M. Nakayama, M. Wada, T. Harada, J. Nagayama, H. Kusaba, and K. Ohshima Hypomethylation status of CpG sites at the promoter region and overexpression of the human MDR1 gene in acute myeloid leukemias Blood 92 1998 4296 4307
9. H. Kusaba, M. Nakaya, T. Harada, M. Nomoto, K. Kohno, M. Kuwano, and M. Wada Association of 5′CpG demethylation and altered chromatin structure in the promoter region with transcriptional activation of the multidrug resistance 1 gene in human cancer cells Eur. J. Biochem. 262 1999 924 932
10. A. El-Osta, P. Kantharidis, J.R. Zalcberg, and A.P. Wolffe Precipitous release of methyl-CpG binding protein and histone deacetylase 1 from the methylated human multidrug resistance gene (MDR1) on activation Mol. Cell. Biol. 22 2002 1844 1857
11. Y. Tada, M. Wada, K. Kuroiwa, N. Kinugawa, T. Harada, and J. Nagayama MDR1 gene overexpression and altered degree of methylation at the promoter region in bladder cancer during chemotherapeutic treatment Clin. Cancer Res. 6 2000 4618 4627
12. A. Harbottle, A.K. Daly, K. Atherton, and F.C. Campbell Role of glutathione S-transferase P1, P-glycoprotein and multidrug resistance-associated protein 1 in acquired doxorubicin resistance Int. J. Cancer 92 2001 777 783
13. M.G. House, M. Guo, C. Iacobuzio-Donahue, and J.G. Herman Molecular progression of promoter methylation in intraductal papillary micinous neoplasms (IPMN) of the pancreas Carcinogenesis 24 2003 193 198
14. S.J. Clark, J. Harrison, C.L. Paul, and M. Frommer High sensitivity mapping of methylated cytosines Nucleic Acid Res. 22 1994 2990 2997
15. P. Pakneshan, M. Szyf, R. Farias-Eisner, and S.A. Rabbani Reversal of the hypomethylation status of urokinase (uPA) promoter blocks breast cancer growth and metastasis J. Biol. Chem. 279 2004 31735 31744
16. H. Enokida, H. Shiina, M. Igawa, T. Ogishima, T. Kawakami, and W.W. Bassett CpG hypermethylation of MDR1 gene contributes to the pathogenesis and progression of human prostate cancer Cancer Res. 64 2004 5956 5962
17. G.L. David, S. Yegnasubramanian, A. Kumar, V.L. Marchi, A.M. De Marzo, X. Lin, and W.G. Nelson MDR1 promoter hypermethylation in MCF-7 human breast cancer cell: changes in chromatin structure induced by treatment with 5-aza-cytidine Cancer Biol. Ther. 3 2004 540 548
18. Y. Guo, P. Pakneshan, J. Gladu, A. Slack, M. Szyf, and S.A. Rabbani Regulation of DNA methylation in human breast cancer J. Biol. Chem. 277 2000 41571 41579
19. P. Pakneshan, B. Tetu, and S.A. Rabbani Demethylation of urokinase promoter as a prognostic marker in patients with breast carcinoma Clin. Cancer Res. 10 2004 3035 3041
20. M.A. dit Faute, L. Laurent, D. Ploton, M.F. Poupon, J.C. Jardillier, and H. Bobinchon Distinctive alterations of invasiveness, drug resistance and cell-cell organization in 3D-cultures of MCF-7, a human breast cancer cell line, and its multidrug resistant variant Clin. Exp. Metastasis 19 2002 161 168
21. R.H. Xing, and S.A. Rabbani Transcriptional regulation of urokinase (uPA) gene expression in breast cancer cells: role of DNA methylation Int. J. Cancer 81 1999 443 450